Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction.

 

The cardiovascular innovation cycle presented by TCT Course Director Martin Leon, M.D. at TCT 2018. #TCT2018 #TCT #TCT18

The cardiovascular innovation cycle, presented by TCT Course Director Martin Leon, M.D., at TCT 2018.

Blog | Cath Lab | October 16, 2018

There is a hype cycle surrounding new technologies in all industries, but medicine is unique because of its focus on...

Bioresorbable stents (BRS) in development presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward. #TCT #TCT2018

Bioresorbable stents (BRS) in development, presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward.

Feature | Stents Bioresorbable | October 12, 2018 | Dave Fornell, Editor

Bioresorbable stent (BRS) technology is not dead, but the unbridled enthusiasm seen two years ago for the technology...

A comparison of target lesion failure (TLF) of the Reva bioresorbable stent to the Absorb and top performing metallic DES. #TCT #TCT2018 #TCT18 #BRS #bioresorbablestents #bioresorbablescaffolds

A comparison of target lesion failure (TLF) of the Reva bioresorbable stent to the Absorb and top performing metallic DES. 

News | Stents Bioresorbable | October 12, 2018

October 12, 2018 – Reva Medical presented four key data sets demonstrating the capabilities of the company’s Fantom...

Videos | October 11, 2018

A discussion with Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president,...

Videos | TCT | October 03, 2018

DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the...

Magnitude Bioresorbable Scaffold Shows Low MACE, Restenosis Rates at Nine Months
News | Stents Bioresorbable | October 01, 2018

October 1, 2018 — New results from the RENASCENT studies presented at the Transcatheter Cardiovascular Therapeutics...

Videos | Stents Bioresorbable | August 06, 2018

Patrick Serruys, M.D., Ph.D., Imperial College London, explains where development of bioresorbable scaffolds stands...

Amaranth's Fortitute bioresorbable stent scaffold. The company is developing smaller strut BRS.  Data presented at EuroPCR 2018
Feature | Stents Bioresorbable | June 19, 2018

June 19, 2018 – Amaranth Medical offered new details about its 85-micron Defiance bioresorbable scaffold (BRS)...

Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018

January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling...

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell

There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or...

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017

November 8, 2017 – New results from the HARMONEE Japan/U.S. Registration Trial, reported by in a first report...

Videos | Stents Bioresorbable | November 07, 2017

A discussion with Ajay Kirtane, M.D., SM, director of the cardiac catheterization laboratories at New York-...

Thirty-Day ABSORB IV Results Demonstrate Improvements Still Needed in Bioresorbable Stents
News | Stents Bioresorbable | October 31, 2017

October 31, 2017 – Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting...

FDA Investigating Increased Major Adverse Cardiac Event Rates of Absorb Bioresorbable Stent
News | Stents Bioresorbable | October 31, 2017

October 31, 2017 — The U.S. Food and Drug Administration (FDA) issued a warning to healthcare providers that interim...

Overlay Init